Spots Global Cancer Trial Database for Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer
Official Title: Phase II Clinical Study of Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
Study ID: NCT06102772
Conditions
Interventions
Study Description
Brief Summary: This is a prospective, single-center, open, single-arm clinical study to observe and evaluate the efficacy and safety of Fruquintinib and Adebrelimab combined with paclitaxel/albumin paclitaxel for second-line treatment of advanced gastric cancer.
Detailed Description: The benefits of immunotherapy in first-line treatment for gastric cancer patients whose tumor tissue CPS\<5 are limited. And some patients have not been treated by immunotherapy in the first-line treatment in clinical practice. This study intends to enroll first-line patients with advanced gastric cancer who have not been treated with PD-1 antibody, and explore the effectiveness and safety of second-line PD-L1 antibody combined with Fruquintinib and paclitaxel/albumin-paclitaxel, providing clues for the application of PD-L1 antibody in advanced gastric cancer.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Contact Details
Name: Ting Deng, MD
Affiliation: Tianjin Medical University Cancer Institute and Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
